These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 2921776

  • 21. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR.
    J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
    [Abstract] [Full Text] [Related]

  • 22. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.
    Reber U, Wüllner U, Trepel M, Baumgart J, Seyfried J, Klockgether T, Dichgans J, Weller M.
    Biochem Pharmacol; 1998 Feb 01; 55(3):349-59. PubMed ID: 9484802
    [Abstract] [Full Text] [Related]

  • 23. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K, Shrieve DC.
    J Natl Cancer Inst; 1987 Oct 01; 79(4):811-5. PubMed ID: 3477662
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma.
    Moynihan K, Elion GB, Pegram C, Reist CJ, Wellner D, Bigner DD, Griffith OW, Friedman HS.
    Cancer Chemother Pharmacol; 1997 Oct 01; 39(3):179-86. PubMed ID: 8996517
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.
    Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF.
    Biochem Pharmacol; 1985 Jul 15; 34(14):2583-6. PubMed ID: 4040369
    [No Abstract] [Full Text] [Related]

  • 30. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF.
    J Clin Oncol; 1996 Jan 15; 14(1):249-56. PubMed ID: 8558205
    [Abstract] [Full Text] [Related]

  • 31. Glutathione depletion in tissues after administration of buthionine sulphoximine.
    Minchinton AI, Rojas A, Smith KA, Soranson JA, Shrieve DC, Jones NR, Bremner JC.
    Int J Radiat Oncol Biol Phys; 1984 Aug 15; 10(8):1261-4. PubMed ID: 6469748
    [Abstract] [Full Text] [Related]

  • 32. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
    Dethlefsen LA, Lehman CM, Biaglow JE, Peck VM.
    Radiat Res; 1988 May 15; 114(2):215-24. PubMed ID: 3375425
    [Abstract] [Full Text] [Related]

  • 33. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC.
    Cancer Res; 1993 May 01; 53(9):2066-70. PubMed ID: 8097674
    [Abstract] [Full Text] [Related]

  • 34. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
    Hansson J, Edgren M, Ehrsson H, Ringborg U, Nilsson B.
    Cancer Res; 1988 Jan 01; 48(1):19-26. PubMed ID: 3334994
    [Abstract] [Full Text] [Related]

  • 35. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
    Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ.
    Cancer Res; 1995 Oct 15; 55(20):4507-11. PubMed ID: 7553617
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer.
    Berger SJ, Gosky D, Zborowska E, Willson JK, Berger NA.
    Cancer Res; 1994 Aug 01; 54(15):4077-83. PubMed ID: 8033140
    [Abstract] [Full Text] [Related]

  • 38. [Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].
    Bier H.
    Laryngorhinootologie; 1990 Jan 01; 69(1):16-20. PubMed ID: 2310456
    [Abstract] [Full Text] [Related]

  • 39. Cellular glutathione depletion by diethyl maleate or buthionine sulfoximine: no effect of glutathione depletion on the oxygen enhancement ratio.
    Mitchell JB, Russo A, Biaglow JE, McPherson S.
    Radiat Res; 1983 Nov 01; 96(2):422-8. PubMed ID: 6647769
    [Abstract] [Full Text] [Related]

  • 40. Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine.
    Ono K, Shrieve DC.
    Int J Radiat Oncol Biol Phys; 1986 Jul 01; 12(7):1175-8. PubMed ID: 3091546
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.